about
Evaluation of drug penetration into the brain: a double study by in vivo imaging with positron emission tomography and using an in vitro model of the human blood-brain barrier.Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary CancerMonitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinomaExperimental Approach to Evaluate the 11C Perfusion and Diffusion in Small Animal Tissues for HadronPET Applications.Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases.In vivo biodistribution and pharmacokinetics of 18F-labelled Spiegelmers: a new class of oligonucleotidic radiopharmaceuticals.Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening.Synthesis, radiolabeling with fluorine-18 and preliminary in vivo evaluation of a heparan sulphate mimetic as potent angiogenesis and heparanase inhibitor for cancer applications.Differential influence of propofol and isoflurane anesthesia in a non-human primate on the brain kinetics and binding of [(18)F]DPA-714, a positron emission tomography imaging marker of glial activation.Synthesis of 6-[¹⁸F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET.PET imaging of medullary thyroid carcinoma in MEN2A transgenic mice using 6-[(18)F]F-L-DOPA.[18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates.Design and synthesis of a new [18F]fluoropyridine-based haloacetamide reagent for the labeling of oligonucleotides: 2-bromo-N-[3-(2-[18F]fluoropyridin-3-yloxy)propyl]acetamide.Genotype specific age related changes in a transgenic rat model of Huntington's disease.1-[3-(2-[18F]fluoropyridin-3-yloxy)propyl]pyrrole-2,5-dione: design, synthesis, and radiosynthesis of a new [18F]fluoropyridine-based maleimide reagent for the labeling of peptides and proteins.Fluorine-18-labeled phospholipid quantum dot micelles for in vivo multimodal imaging from whole body to cellular scales.Imaging the neuroimmune response to alcohol exposure in adolescent baboons: a TSPO PET study using (18) F-DPA-714.Avidin/Biotin Bioinspired Platform for Dual In Vivo 18F-PET/NIRF Molecular Imaging.Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide.Optimized Quantification of Translocator Protein Radioligand ¹⁸F-DPA-714 Uptake in the Brain of Genotyped Healthy Volunteers.From Structure-Activity Relationships on Thiazole Derivatives to the In Vivo Evaluation of a New Radiotracer for Cannabinoid Subtype 2 PET Imaging.Evaluation of TSPO PET imaging, a marker of glial activation, to study the neuroimmune footprints of morphine exposure and withdrawal.Synthesis and radiolabeling of N-[4-[4-(2-[11C]methoxyphenyl)piperazin-1-yl]butyl]benzo[b]thiophene-2-carboxamide -- a potential radiotracer for D3 receptor imaging with PET.Characterization of a synthetic anionic vector for oligonucleotide delivery using in vivo whole body dynamic imaging.Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.Preparation and evaluation of novel pyrazolo[1,5-a]pyrimidine acetamides, closely related to DPA-714, as potent ligands for imaging the TSPO 18kDa with PET.Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease.Diagnostic value of combining ¹¹C-choline and ¹⁸F-FDG PET/CT in hepatocellular carcinoma.Novel Pyrazolo[1,5-a]pyrimidines as Translocator Protein 18 kDa (TSPO) Ligands: Synthesis, in Vitro Biological Evaluation, [(18)F]-Labeling, and in Vivo Neuroinflammation PET Images.[18F]DPA-C5yne, a novel fluorine-18-labelled analogue of DPA-714: radiosynthesis and preliminary evaluation as a radiotracer for imaging neuroinflammation with PET.[18F]DPA-714, [18F]PBR111 and [18F]FEDAA1106-selective radioligands for imaging TSPO 18 kDa with PET: automated radiosynthesis on a TRACERLAb FX-FN synthesizer and quality controls.In vivo imaging of brain lesions with [(11)C]CLINME, a new PET radioligand of peripheral benzodiazepine receptors.Positron Emission Tomography Imaging Reveals an Importance of Saturable Liver Uptake Transport for the Pharmacokinetics of Metoclopramide.Fluorine-18 labelling of a series of potential EGFRvIII targeting peptides with a parallel labelling approach using [18F]FPyMEComparison of [18F]FBA and [18F]FPyMe as peptide radio-labeling agents of PEPHC1 for PET imaging of EGFRvIIIGeneral method to label antisense oligonucleotides with radioactive halogens for pharmacological and imaging studiesSingle photon emission computed tomography/positron emission tomography imaging and targeted radionuclide therapy of melanoma: new multimodal fluorinated and iodinated radiotracersIn vivo validation of free-space fluorescence tomography using nuclear imagingSynthesis, radiolabeling and preliminary in vivo evaluation of multimodal radiotracers for PET imaging and targeted radionuclide therapy of pigmented melanomaEasy upgrade of the TRACERLab FX C Pro for [¹¹C]carboxylation reactions: application to the routine production of [1-¹¹C]acetate
P50
Q33990556-2B1FB073-163F-47FB-BAFF-FEDF98ECA185Q34503914-C81966E6-D348-42C1-866E-13399E2B2EF1Q35703904-E5442AD7-C516-4B3A-AEA7-24C8C8A04BAFQ35970333-5F3C0791-D0B4-4BB9-B82A-A95649C72497Q38018550-8245A1E8-67B4-4382-ABE7-E66904B1BBC4Q38332794-223FA857-2D0D-4F28-9A62-7FF2C172DE89Q39592140-78D32300-7A7F-401A-99DC-F7DEFA2A019DQ40117104-CCAA891E-EAFB-42EB-8C80-F797A3733B76Q40952031-31C5776D-FAB9-4DCC-B0D5-74547C026C1FQ42730832-3099C75E-834D-457C-B48A-FB0296825288Q43298565-7B36FE98-3A9C-4D95-8342-10E3B5D5A3A5Q44735126-EB4B5A63-3197-4A60-A9F4-1DEA1B73DCFCQ44900275-0186AC1B-1CEA-4CA7-8920-535F3440A1D0Q45303655-2D3DE41E-F0F8-44CC-9C65-3805CB7C9C61Q46380200-3B6862F6-5845-4D52-9EA2-8ABC580B0F17Q47377302-39C4FA74-9ADB-4C48-B1DB-DF34E0C7040DQ47750146-9607D558-14BD-43EB-8C22-EB37E1024186Q47771672-B6436A33-0FCD-46B0-98D3-080D3378FCBFQ47932905-3900B270-AEE1-437F-A389-E798442F8A84Q48153600-3804AF34-0644-4F23-841C-4B37E843D224Q48258908-6321115A-84E4-4D01-B9FB-B2B3149166F2Q48420378-DDF302A2-EA54-46E3-A56B-F5FDD7EB9E83Q48436659-ADABC9F5-6034-401C-A7D6-55FD2CA2EB61Q48594354-2981BB06-2C3E-42B6-88B5-3D9EEC2D6321Q48685512-04355313-F15C-4C99-88DD-CBDE13AD9B25Q51752038-EE1D560F-A656-4BE1-9AD3-DCBA4D53A184Q52613236-5892FEE8-E21E-4825-9C88-0A0A67498AE8Q52988390-D21E49F6-CD87-4EF4-97F1-764955C44DE5Q52991577-7B701538-B7A8-4CC5-A761-441B0EDEE799Q53068160-4F1DA2EC-FF80-47D4-8CE4-BEA252D4A659Q53190181-1091CD34-E0A0-4A89-AFA6-B3EAE14090C6Q53469733-9678FB8C-C851-4665-8684-44969639C903Q55025065-2B5FB66F-E497-44C9-B88A-655043EEB0D0Q57681945-2F6B8532-5DE5-4270-AB8F-EDFC55F11A3FQ57682061-9299439F-9D19-45A8-8155-33097D25CD5EQ74337134-29618925-7BDC-41BE-A208-1E2C7807E97EQ83644305-C9358D89-024A-4D2E-A7E3-8E0A3A31A950Q85041930-4F88CD29-6FB9-4991-A553-4FECEE06CB72Q86631694-D992D801-3DD2-4F9F-B59F-FA32573B3891Q87248145-FF0543BB-7D07-402D-B138-E95CEBDF8136
P50
description
researcher ORCID ID = 0000-0002-5035-4072
@en
wetenschapper
@nl
name
Bertrand Kuhnast
@ast
Bertrand Kuhnast
@en
Bertrand Kuhnast
@es
Bertrand Kuhnast
@nl
type
label
Bertrand Kuhnast
@ast
Bertrand Kuhnast
@en
Bertrand Kuhnast
@es
Bertrand Kuhnast
@nl
prefLabel
Bertrand Kuhnast
@ast
Bertrand Kuhnast
@en
Bertrand Kuhnast
@es
Bertrand Kuhnast
@nl
P106
P1153
6602885094
P31
P496
0000-0002-5035-4072